Actualités et communiqués de presse iBio 2026 | IBIO | ISIN US4510337086

Actualités Eulerpool iBio

03/01/2025 17:03:59

iBio stärkt Präsenz im Biotech-Sektor durch strategische Partnerschaft mit AstralBio

Actualités de l'action iBio

iBio est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant iBio.

17 mars·
SeekingAlpha
iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript
16 mars·
Benzinga
iBio, Inc. To Host Call On PH-HFpEF Pipeline Expansion, Targets Bispecific Antibody Candidate Selection In Q3 2026
9 mars·
Benzinga
iBio Reports Early Study Results Showing Experimental Obesity Drug Reduced Fat in Animals
3 mars·
Benzinga
Jones Trading Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7
27 février·
Benzinga
iBio Enters $100M At-The-Market Offering Agreement With Jefferies LLC; Terminates Prior $7.35M ATM Program
27 février·
Benzinga
iBio Files Preliminary Prospectus To Issue Up To $200M In Securities
24 février·
Yahoo
iBio to Participate in Upcoming Investor Conferences
12 février·
Benzinga
Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target
10 février·
Yahoo
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
10 février·
Benzinga
iBio Earnings Review: Q2 Summary
3 février·
Yahoo
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
2 février·
Yahoo
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
30 janvier·
Benzinga
iBio Files Prospectus For Resale Of 11,061,738 Shares Of Common Stock By Selling Stockholders
9 janvier·
Benzinga
iBio shares are trading higher after the company announced a $26 million private placement.
9 janvier·
Yahoo
iBio Announces $26 Million Private Placement
9 janvier·
Benzinga
iBio Announces Private Placement Of Approximately $26M
20 décembre·
Yahoo
iBio Insiders Placed Bullish Bets Worth US$655.0k
17 décembre·
Benzinga
EcoR1 Capital Reports 9.9% Passive Stake In IBio As Of Dec 10
10 décembre·
Yahoo
BC-Most Active Stocks
10 décembre·
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session

Communiqués de presse relatifs à l'action iBio

iBio publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

16 août•
iBio
iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate
18 mai•
iBio
iBio to Participate in the H.C. Wainwright Global Investment Conference
12 mai•
iBio
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
9 mai•
iBio
iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
5 mai•
iBio
iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
2 mai•
iBio
iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
11 mars•
iBio
iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference
15 février•
iBio
Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors
14 février•
iBio
iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update
7 février•
iBio
iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022
26 janvier•
iBio
iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease
4 janvier•
iBio
iBio Announces Participation in the H.C. Wainwright BioConnect Conference
22 décembre•
iBio
iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022
21 décembre•
iBio
iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting
10 décembre•
iBio
iBio Announces Partial Adjournment of Annual Meeting to December 22
30 novembre•
iBio
ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting
29 novembre•
iBio
Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202
17 novembre•
iBio
Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting
15 novembre•
iBio
iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update
15 novembre•
iBio
iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors
8 novembre•
iBio
iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021
3 novembre•
iBio
iBio Acquires FastPharming Manufacturing Facility®
26 octobre•
iBio
iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9
27 septembre•
iBio
iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
20 septembre•
iBio
iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference
20 septembre•
iBio
iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021
7 septembre•
iBio
iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
26 août•
iBio
iBio Appoints William D. Clark to its Board of Directors
25 août•
iBio
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics
15 juillet•
iBio
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

iBio News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action iBio (IBIO, ISIN : US4510337086). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez iBio.